Iconovo’s ICOone® inhaler platform receives new patent approval in the US

The United States Patent and Trademark Office (USPTO) intends to approve an additional patent for ICOone®, Iconovo’s nnovative inhaler platform that enables convenient and cost-effective administration of vaccines and biologics. Iconovo is already pursuing several development projects based on ICOone®, including one with financial support from the Bill & Melinda Gates Foundation.

ICOone® is Iconovo’s inhaler platform for convenient and cost-effective administration of vaccines and biologics. Since ICOone® can be loaded with the active ingredient in the form of a dry powder, expensive and complicated cold storage is not required. In addition, it avoids the handling of disposable syringes and used needles that can spread blood-borne infections. Today’s announcement from the USPTO means that ICOone® will be protected by two patents in the US market. The inhaler also has patent protection inthe rest of Europe (EPO), India, China, and Japan.